Magnetic Resonance Evaluation of Brain Metastases With Two Doses of Gadobutrol 1.0 M

Single center, Open-label Study to evaluate the efficacy (by blinded reading) and safety of MRI in patient suspected Metastases with two dose of Gadobutrol

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-DDT-11001729

Enrollment

Unknown

Registered

2011-11-24

Start date

2011-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Metastasis

Interventions

Gold Standard:

Index test:

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patient whose primary tumor is diagnosed with 1 year and who was suspected cerebral metastasis according symptom; 2. Patient who was highly suspected cerebral metastasis due to the intracranial lesion detected by the CT etc, no matter the primary tumor is not found; 3. Willing to sign the ICF.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients who have any contraindication to MRI or CE-MRI; 3. Patients who was treated for his/ her cerebral metastasis before this study; 4. Patient who is sensitive to any component of the MRI contrast agent or patient who has the history of severe allergy or allergic asthma; 5. Patients whose eGFR<60 ml/min/1.73 m2.

Design outcomes

Primary

Measure	Time frame
The number of brain metastasis lesion;	—

Secondary

Measure	Time frame
The CNR & SNR of the metastasis lesion;The diagnosis value of MRI imagine;safety;	—

Countries

China

Contacts

Public ContactBenyang Qiang

bqyang888@sina.com+86 13309886610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026